Dutch CD­MO In­travacc gets NIH grant of up to $14.6M to make gon­or­rhea vac­cine

To date, on­ly two gon­or­rhea vac­cines have made it in­to hu­man tri­als, with nei­ther prov­ing suc­cess­ful.

In­travacc and Ther­a­pyx hope to make the third — and In­travacc, a Dutch CD­MO, has now re­ceived a grant from NI­AID for up to $14.6 mil­lion to push their vac­cine can­di­date to­wards the clin­ic, In­travacc said on Wednes­day.

The vac­cine, dubbed NGoX­IM, con­sists of IL-12 cap­sules in­side an out­er mem­brane vesi­cle en­gi­neered by In­travacc, and it would be de­liv­ered through the nose. In 2020, Ther­a­pyx got a $2.8 mil­lion NIH SIBR grant to de­vel­op the vac­cine, which puts IL-12 in­to tiny cap­sules that are made specif­i­cal­ly for de­liv­ery through the nose.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER